Cargando…
Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer
93 patients with hormone refractory metastatic prostate cancer were entered on a prospective study to measure reduction in pain and changes in quality of life (QoL) after the administration of 150 MegaBequerel (MBq) Strontium-89 (Sr-89). QoL was assessed using a validated instrument, the Functional...
Autores principales: | Turner, S L, Gruenewald, S, Spry, N, Gebski, V |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363737/ https://www.ncbi.nlm.nih.gov/pubmed/11161391 http://dx.doi.org/10.1054/bjoc.2000.1610 |
Ejemplares similares
-
Strontium-89 therapy for the treatment of huge osseous metastases in prostate carcinoma: A case report
por: ZHANG, WENJIE, et al.
Publicado: (2013) -
89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes.
por: Fosså, S. D., et al.
Publicado: (1992) -
In Vitro Study on Apoptosis Induced by Strontium-89 in Human
Breast Carcinoma Cell Line
por: Wang, Cheng, et al.
Publicado: (2011) -
Does Less Pain Predict Better Quality of Life among Malaysian Patients with Mild–Moderate Knee Osteoarthritis?
por: Mohd Yusuf, Salma Yasmin, et al.
Publicado: (2022) -
Non-Adaptive MR-Guided Radiotherapy for Prostate SBRT: Less Time, Equal Results
por: Sandoval, Maria L., et al.
Publicado: (2021)